Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Income from Continuing Operations (2019 - 2025)

Keros Therapeutics' Income from Continuing Operations history spans 7 years, with the latest figure at 23461000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 49.03% year-over-year to 23461000.0; the TTM value through Dec 2025 reached 87014000.0, up 146.44%, while the annual FY2025 figure was 87014000.0, 146.44% up from the prior year.
  • Income from Continuing Operations reached 23461000.0 in Q4 2025 per KROS's latest filing, down from 7280000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 148451000.0 in Q1 2025 to a low of 52956000.0 in Q3 2024.
  • Average Income from Continuing Operations over 5 years is 21685150.0, with a median of 28492000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: crashed 328.21% in 2022, then surged 444.32% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 6940000.0 in 2021, then plummeted by 328.21% to 29718000.0 in 2022, then crashed by 56.32% to 46455000.0 in 2023, then grew by 0.92% to 46026000.0 in 2024, then surged by 49.03% to 23461000.0 in 2025.
  • Per Business Quant, the three most recent readings for KROS's Income from Continuing Operations are 23461000.0 (Q4 2025), 7280000.0 (Q3 2025), and 30696000.0 (Q2 2025).